Literature DB >> 34514677

Association between discontinuing chronic opioid therapy and newly diagnosed substance use disorders, accidents, self-inflicted injuries and drug overdoses within the prescribers' health care system: a retrospective cohort study.

Corey J Hayes1,2, Erin E Krebs3,4, Chenghui Li5, Joshua Brown6, Teresa Hudson1,2, Bradley C Martin6.   

Abstract

BACKGROUND AND AIM: Prescribers are commonly confronted with discontinuing opioid therapy among patients prescribed chronic opioid therapy (COT). This study aimed to measure the association between discontinuing COT and diagnoses of substance use disorders (SUDs) and opioid-related adverse outcomes (AOs).
DESIGN: Retrospective cohort study.
SETTING: United States Veterans Healthcare Administration. PARTICIPANTS: Veterans with chronic pain on COT who discontinued opioid therapy were compared with those continuing COT using data from fiscal years 2009 to 2015. MEASUREMENTS: Newly diagnosed substance use disorders (SUD composite; individual types: opioid, non-opioid drug and alcohol use disorders) and opioid-related adverse outcomes (AO composite; individual types: accidents resulting in wounds/injuries, opioid-related accidents/overdoses, alcohol and non-opioid medication-related accidents/overdoses, self-inflicted injuries and violence-related injuries) were evaluated. Primary analyses were conducted using 1:1 matching of discontinuers with those continuing COT based on propensity score and index date (±180-day window). Sensitivity analyses were conducted using logistic regressions with stabilized inverse probability of treatment weighting (SIPTW) and instrumental variable (IV) models.
FINDINGS: A total of 15 695 (75.4%) and 17 337 (76.6%) discontinuers were matched with those continuing COT among the cohorts testing SUD and AO development respectively. In the primary propensity score matched analyses, the composite SUD outcome was not different between discontinuers and those continuing COT (OR = 0.932, 95% CI = 0.850, 1.022). The composite AO outcome was lower among discontinuers (OR = 0.660, 95% CI = 0.623, 0.699) compared with those continuing COT. SIPTW analyses found lower SUD (OR = 0.789, 95% CI = 0.743, 0.837), and AO (OR = 0.660, 95% CI = 0.623, 0.699) rates among discontinuers. IV models found mixed and sometimes contradictory results.
CONCLUSIONS: Discontinuing patients from chronic opioid therapy appears to be associated with decreased diagnoses for opioid-related adverse outcomes. The association with substance use disorders appears to be inconclusive.
© 2021 Society for the Study of Addiction.

Entities:  

Keywords:  Chronic opioid therapy discontinuation; opioid overdose; opioid prescribing; opioid-related adverse outcomes; opioids; substance use disorders

Mesh:

Substances:

Year:  2021        PMID: 34514677      PMCID: PMC8904270          DOI: 10.1111/add.15689

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  25 in total

1.  Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan.

Authors:  Karen H Seal; Ying Shi; Gregory Cohen; Beth E Cohen; Shira Maguen; Erin E Krebs; Thomas C Neylan
Journal:  JAMA       Date:  2012-03-07       Impact factor: 56.272

2.  Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders.

Authors:  Travis I Lovejoy; Benjamin J Morasco; Michael I Demidenko; Thomas H A Meath; Joseph W Frank; Steven K Dobscha
Journal:  Pain       Date:  2017-03       Impact factor: 6.961

3.  Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified.

Authors:  Jessica J Wyse; Benjamin J Morasco; Steven K Dobscha; Michael I Demidenko; Thomas H A Meath; Travis I Lovejoy
Journal:  J Opioid Manag       Date:  2018 Jul/Aug

4.  An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program.

Authors:  Gerald Cochran; Adam J Gordon; Wei-Hsuan Lo-Ciganic; Walid F Gellad; Winfred Frazier; Carroline Lobo; Chung-Chou H Chang; Ping Zheng; Julie M Donohue
Journal:  Med Care       Date:  2017-03       Impact factor: 2.983

5.  Development and applications of the Veterans Health Administration's Stratification Tool for Opioid Risk Mitigation (STORM) to improve opioid safety and prevent overdose and suicide.

Authors:  Elizabeth M Oliva; Thomas Bowe; Sara Tavakoli; Susana Martins; Eleanor T Lewis; Meenah Paik; Ilse Wiechers; Patricia Henderson; Michael Harvey; Tigran Avoundjian; Amanuel Medhanie; Jodie A Trafton
Journal:  Psychol Serv       Date:  2017-02

6.  Risk Factors of Prescription Opioid Overdose Among Colorado Medicaid Beneficiaries.

Authors:  Piyameth Dilokthornsakul; Gina Moore; Jonathan D Campbell; Robert Lodge; Cathy Traugott; Judy Zerzan; Richard Allen; Robert L Page
Journal:  J Pain       Date:  2015-12-22       Impact factor: 5.820

7.  Patterns of opioid use for chronic noncancer pain in the Veterans Health Administration from 2009 to 2011.

Authors:  Mark J Edlund; Mark A Austen; Mark D Sullivan; Bradley C Martin; James S Williams; John C Fortney; Teresa J Hudson
Journal:  Pain       Date:  2014-08-29       Impact factor: 6.961

8.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  MMWR Recomm Rep       Date:  2016-03-18

9.  Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study.

Authors:  Mark D Sullivan; Mark J Edlund; Ming-Yu Fan; Andrea DeVries; Jennifer Brennan Braden; Bradley C Martin
Journal:  Pain       Date:  2010-06-15       Impact factor: 6.961

10.  Instrumental variable methods for causal inference.

Authors:  Michael Baiocchi; Jing Cheng; Dylan S Small
Journal:  Stat Med       Date:  2014-03-06       Impact factor: 2.373

View more
  1 in total

1.  Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain: systematic review and meta-analysis.

Authors:  Nicholas Avery; Amy G McNeilage; Fiona Stanaway; Claire E Ashton-James; Fiona M Blyth; Rebecca Martin; Ali Gholamrezaei; Paul Glare
Journal:  BMJ       Date:  2022-04-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.